Palliative Systemic Therapy in Advanced Thymic Epithelial Tumors in 2026-A Narrative Review

Area of Science:

• Oncology
• Medical Research

Background:

• Palliative systemic therapy for advanced thymic epithelial tumors (TET) is difficult due to limited evidence and tumor heterogeneity.
• Current treatment relies on cross-trial comparisons of small, non-randomized studies.

Purpose of the Study:

• To critically appraise current and novel systemic therapies for advanced thymic epithelial tumors.
• To evaluate the efficacy of platinum-based chemotherapy, anthracyclines, antiangiogenic drugs, and immune checkpoint inhibitors.
• To explore targeted therapies, biomarkers, and investigational treatments for thymic malignancies.

Main Methods:

• Review of scientific literature focusing on palliative systemic therapy for advanced thymic epithelial tumors.
• Critical appraisal of clinical trial data, including non-randomized studies.
• Analysis of genomic data, biomarkers (KIT, HER2), and investigational drug classes.

Main Results:

• Platinum-based combination chemotherapy remains the standard first-line treatment for TET.
• The addition of anthracyclines to platinum-based chemotherapy in thymoma is questioned.
• New combinations with antiangiogenic drugs and immune checkpoint inhibitors show promise for thymic carcinoma.
• Genomic-based targeted therapy has limited benefit for most patients.

Conclusions:

• There is a need to challenge established treatment paradigms for advanced thymic epithelial tumors.
• Novel therapeutic strategies, including immunotherapy and targeted agents, require further investigation.
• Biomarker discovery and optimized research designs are crucial for advancing TET treatment.